Every 10-Q that REGEN BIOPHARMA PFD A (RGBPP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RGBPP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGBPP filings page.
Regen BioPharma, Inc. (RGBP) reported minimal operations with $177,194 in net revenue for the nine months ended June 30, 2026, essentially flat versus 2025. Revenue comes entirely from license agreements, including related-party Zander Therapeutics and Oncology Pharma.
Operating expenses rose to $857,999, driving an operating loss of $680,805. After net other income of $67,094 (mainly derivative fair-value gains), the net loss was $613,711, modestly better than the prior-year loss of $702,033. The balance sheet is very weak: cash was only $239 against total liabilities of $6,165,793, including a derivative liability of $1,901,963, and a working capital deficit of about $5.9 million. Accumulated deficit reached $22,305,331 and stockholders’ deficit was $(5,878,206). The company issued over 800 million shares to convert debt, interest and fees, plus additional shares for cash and compensation, creating significant dilution. Management discloses substantial doubt about the company’s ability to continue as a going concern and states that disclosure controls and procedures were ineffective.
Regen BioPharma, Inc. reported very small revenue but headline profitability for the quarter ended March 31, 2026. Net revenue was $59,065 for the quarter and $118,129 for the six months, essentially flat versus the prior year and largely from license agreements, including related-party Zander Therapeutics.
The company posted quarterly net income of $991,927 and six‑month net income of $24,074, driven mainly by a non‑cash derivative income gain of $1,181,680 for the quarter and $800,854 year‑to‑date from revaluing convertible note derivatives, while operating losses widened to $153,709 for the quarter and $705,333 for six months as research, consulting and general expenses increased.
Liquidity is extremely tight: cash was only $271 at March 31, 2026, with total current liabilities of $5,619,062, a working capital deficit of about $5.3 million, an accumulated deficit of $21,667,546, and a derivative liability of $1,278,763. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern and plans to rely on additional equity or debt financing.
The balance sheet is highly leveraged to convertible debt; convertible notes payable (net of discount) were $817,717, and multiple older notes remain outstanding on deeply discounted conversion terms. To reduce debt and pay fees and interest, Regen issued 232,272,777 common shares in the six months ended March 31, 2026, plus 11,111,111 shares for $50,000 cash, and later a further 160,519,051 shares after quarter‑end, leading to significant dilution.
Capital structure is complex, with 351,438,592 common shares outstanding at March 31, 2026 and, as of May 1, 2026, 511,957,643 common shares plus large preferred series, including 154,760,498 Series A shares following a stock dividend of 144,636,727 Series A Preferred on February 9, 2026. One lawsuit seeking $398,740 plus fees is pending in California state court, with settlement discussions underway. Management also concludes that disclosure controls and procedures were ineffective.
Regen BioPharma, Inc. reported another heavy loss for the quarter ended December 31, 2025, while remaining in an early-stage development phase with no approved products. Net revenue was modest at $59,065, unchanged from the prior-year quarter and largely driven by license agreements with Oncology Pharma and related-party Zander Therapeutics.
Operating expenses climbed sharply to $610,689 from $120,443, mainly due to $210,000 in research and development spending and substantially higher general and administrative costs. The company posted an operating loss of $551,624 and a net loss of $967,853, widening from $515,384 a year earlier, while also recording significant derivative expense tied to its convertible notes.
Liquidity remains strained. Cash fell to just $4,578 and total assets were $237,076 against current liabilities of $6,810,073, leaving a stockholders’ deficit of $(6,572,997) and a derivative liability of $2,460,443. Management explicitly notes “significant doubt” about the company’s ability to continue as a going concern and plans to rely on additional equity and debt financing, including recent share issuances, to fund operations and clinical plans.